July 15, 2009New England Journal of Medicine
Prasugrel in Clinical Practice
Key result
The FDA approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention.
Population
Patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention (PCI)
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
The FDA approved prasugrel in 2009 for patients with unstable angina or myocardial infarction undergoing PCI.
Key Points
- The research aims to evaluate the clinical benefits of prasugrel in managing unstable angina and myocardial infarction during PCI.
- Approved by the FDA for use in clinical settings on July 10, 2009.
- Involves the use of prasugrel in patients undergoing percutaneous coronary intervention.
- Focus on patient outcomes related to platelet aggregation and overall atherothrombotic disease management.
- Prasugrel effectively inhibits platelet aggregation, leading to better clinical outcomes in PCI procedures.
- The use of prasugrel in conjunction with aspirin has improved the efficacy of stenting in coronary-artery procedures.
Structured PICO
P
Population
Patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention (PCI)
I
Intervention
Prasugrel
The FDA approved prasugrel in 2009 for patients with unstable angina or myocardial infarction undergoing PCI.
Cite This Study
Deepak L. Bhatt (2009) conducted an editorial in Unstable angina or myocardial infarction undergoing PCI. Prasugrel was evaluated. The FDA approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention.